Intellia Q1 net loss $114.3M, cash $707.1M; Phase 3 HAE enrollment on track

Intellia Therapeutics, Inc.

2025-Q1 EPS reported -$1.10 revenue$16,627,000

Net loss $114.3M vs $107.4M in Q1 2024; collaboration revenue $16.6M down from $28.9M.
Cash, cash equivalents and marketable securities $707.1M as of March 31, 2025, down from $861.7M at Dec 31, 2024; expected to fund operations into H1 2027.
Phase 3 HAELO study for hereditary angioedema on track to complete enrollment in Q3 2025; BLA submission anticipated in H2 2026.
First patient dosed in Phase 3 MAGNITUDE-2 for ATTRv-PN; MAGNITUDE (ATTR-CM) enrollment ahead of projections.
RMAT designation granted for nex-z in ATTR-CM; longer-term Phase 1 data presentations planned for H2 2025.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.